The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Fully equipped labs with 75-member team set-up and made operational in <100 days
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
The Theme of the event was 'Building One Health Together – Improving Health Equity'
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Subscribe To Our Newsletter & Stay Updated
